Lipocine Announces First Quarter 2020 Financial and Operational Results

On May 8, 2020 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported financial results for the first quarter ended March 31, 2020, and provided a corporate update (Press release, Lipocine, MAY 8, 2020, View Source [SID1234557403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Quarter and Recent Corporate Highlights

Resubmitted New Drug Application ("NDA") for TLANDO, the Company’s oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males with hypogonadism
The U.S. Food and Drug Administration ("FDA") acknowledged receipt of resubmission and established August 28, 2020 as the target Prescription Drug User Fee Act ("PDUFA") goal date
Received FDA clearance on Investigational New Drug ("IND") application for Phase 2 clinical study with LPCN 1148 for the treatment of non-alcoholic steatohepatitis ("NASH") in cirrhotic patients
Raised $6.0 million in gross proceeds in a registered direct offering of common stock and warrants in February 2020
Received decision from the U.S. Court of Appeals for the Federal Circuit affirming the decision of the United States Patent and Trademark Office ("USPTO") in the patent interference case between Lipocine and Clarus Therapeutics
First Quarter Ended March 31, 2020 Financial Results
Lipocine reported a net loss of $5.8 million, or ($0.14) per diluted share, for the quarter ended March 31, 2020, compared with a net loss of $3.2 million, or ($0.14) per diluted share, for the quarter ended March 31, 2019.

Research and development expenses were $2.5 million for the quarter ended March 31, 2020, compared with $1.9 million for the quarter ended March 31, 2019. The increase in research and development expenses during the three months ended March 31, 2020 was primarily due to increased contract research organization and outside consulting and manufacturing costs for the LPCN 1144 LiFT Phase 2 clinical study in NASH subjects of $1.7 million, a $50,000 increase in costs for TLANDO XR and a $56,000 increase in personnel expense. These increases were offset by a $1.2 million decrease in costs incurred relating to TLANDO, including the completion of the ABPM study and the filing of the NDA in the first half of 2019 and a $12,000 decrease in contract manufacturing costs for LPCN 1107.

General and administrative expenses were $2.1 million for the quarter ended March 31, 2020, compared with $1.2 million for the quarter ended March 31, 2019. The increase in general and administrative expenses during the three months ended March 31, 2020 was primarily due to a $1.0 million increase in legal costs associated with the lawsuit filed against Clarus for patent infringement in April 2019 in addition to costs associated with interference cases filed against Clarus, offset by a $59,000 decrease in personnel costs and a $26,000 decrease in administrative travel expenses.

As of March 31, 2020, Lipocine had $15.6 million of unrestricted cash, cash equivalents and marketable investment securities compared to $14.1 million at December 31, 2019. Additionally, the Company had $5.0 million of restricted cash, which is required to be maintained as cash collateral under the SVB Loan and Security Agreement until TLANDO is approved by the FDA. The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements through at least February 15, 2021.

Chi-Med to Attend Upcoming Investor Conferences

On May 8, 2020 Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) reported that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT) (Press release, Hutchison China MediTech, MAY 8, 2020, https://www.chi-med.com/upcoming-investor-conferences-200508/ [SID1234557429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;
Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and
Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

HJB and Mabspace Biosciences’ Development and Manufacturing Agreement for Novel Humanized Claudin18.2 Monoclonal Antibody Accomplished FDA and NMPA IND Clearance

On May 8, 2020 HJB, a biologics CDMO committed to quality, reliability and speed for each and every CMC package delivered to its partners, reported that its partner Mabspace Biosciences has received Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA), for a humanized Claudin18.2 monoclonal antibody program (Press release, HJB pharma, MAY 8, 2020, View Source [SID1234557431]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per the development and manufacturing agreement between HJB and Mabspace Bioscience, HJB provided one-stop shop end-to-end CMC package for the Claudin18.2 antibody, from DNA synthesis, process development, DS and DP GMP manufacturing to CMC dossier preparation for IND.

"We are thrilled to have achieved dual-filing in such a short time. This is truly a great milestone for us," said Dr. Xueming Qian, Founder and Chief Executive Officer of MabSpace Biosciences. "HJB’s one-of-a-kind platform not only allowed us a speedy IND submission and clearance, but also added more values to our program. We are very excited to have the opportunity to test this differentiated Claudin18.2 antibody in cancer patients and bring more efficacious treatment options to cancer patients around the world."

"Congratulations to Mabspace Bioscience for the dual-IND clearance. We are proud to be the CMC and manufacturing partner to enable this accelerated and high-quality development package," said Dr. Jerry Yang, General Manager of CDMO Business of HJB. "It is fundamental to our CDMO business to create values for our partners. In this case, our efficient and innovative development and manufacturing platform successfully shortened the total program time and further increased the molecule’s biological activity independent of molecule engineering which is typically how other companies approach the challenge and often leads to freedom-to-operate limitations later on."

HJB’s platform approach was proven highly adaptable and robust during this program. After receiving DNA sequence in September 2018, HJB significantly increased this antibody’s ADCC activity through process optimization, delivered GLP toxicology study material in 9 months and completed all CMC work required for FDA and NMPA filing in 14 months. The result dramatically accelerated the overall timeline and allowed the program to reach first-in-human milestone with high quality Phase I clinical material ahead of other competitors.

Since its facility’s first GMP run in mid-2018, HJB has taken on over 20 CDMO projects, delivered 15 batches of GMP products and been recognized by its global partners for quality, reliability and speed. Currently, HJB’s comprehensive capabilities include cell line and cell bank development, process and formulation development, technology transfer and optimization as well as GMP manufacturing, with three DS production lines (500 – 2000L) and a DP fill-and-finish line.

Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study

On May 7, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL (link available here) (Press release, Bio-Techne, MAY 7, 2020, View Source [SID1234557255]). Principal investigators Dr. Ronald Tutrone, Medical Director of Chesapeake Urology, and Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated the ExoDx Prostate test, or EPI, delivered improved patient outcomes over standard of care in a real-world clinical setting that included 72 urologists, 24 sites and more than 1000 patients. The study is the first ever prospective, multi-center, randomized prostate biomarker trial with a blinded control arm conducted in a clinical utility setting, The study was a collaboration between the largest urology practice in Maryland, Chesapeake Urology, and CareFirst Blue Cross Blue Shield of Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The EPI test is a urine-based genomic test that helps inform the prostate biopsy decision. This liquid biopsy test recently received coverage for the VA Healthcare system under the General Services Administration (GSA) award, received a positive coverage decision from Medicare, and is included in the National Comprehensive Cancer Network (NCCN) guidelines for early detection in men for both initial and repeat biopsy. It is performed by Exosome Diagnostics, a Bio-Techne brand, in its CLIA, ISO, and NY certified and CAP-accredited laboratory located in Waltham, Massachusetts. The EPI test is a risk assessment tool that assists physicians and their patients with determining if a prostate biopsy is needed when presented with an ambiguous PSA test result, thereby reducing complications from unnecessary and invasive procedures.

Key findings from the study include:

When implementing the ExoDx Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician’s recommendation to defer prostate biopsy when the test was negative and go through with a biopsy when the test was positive.
Twenty-three percent of patients deferred a biopsy due to the EPI test based on the physician-patient shared decision questionnaire.
In the standard of care setting, many high-grade prostate cancers are missed because not all high-risk men go through with a biopsy.
Due to improved compliance to proceed to biopsy, physicians detected 30% more cases of clinically significant, or high-grade prostate cancer compared to the standard of care control arm.
These findings can have significant implications for both clinical and economic outcomes. According to Dr. Ronald Tutrone, "From a clinical perspective, deferring biopsy can help a patient avoid the undesirable complications from a biopsy, such as pain, hematuria, infection and potentially hospitalization. Many patients are frightened to undergo biopsy procedure; however, introducing an EPI result not only improved compliance to proceed to biopsy, but detected more clinically significant cancers that might have been missed under the standard of care paradigm."

"This study has important implications from an economic perspective," commented Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "Avoiding unnecessary biopsy procedures represents an estimated savings to the healthcare system of $1,400-$4,000 per patient, in addition to added costs treating complications. There are economic consequences to missing high grade prostate cancer as well. Risk stratification tools such as the ExoDx Prostate test provide the right intervention for the right patient at the right time. Publication of this study in a leading urology journal confirms our convictions that the ExoDx Prostate test provides strong clinical utility and economic value to patients, the medical community and private payors."

A nationwide webinar is scheduled for May 21, 2020 to review the study findings in detail. More information can be found on the Exosome Diagnostics website at View Source

Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

On May 7, 2020 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported financial results for its fiscal second quarter ended March 31, 2020 (Press release, Arrowhead Research Corporation, MAY 7, 2020, View Source [SID1234557271]). The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at View Source For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7566917.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 7566917.

Selected Recent Events

Dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNAi therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis

Completed enrollment of the first sequential cohort in the AROAAT2002 study, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease

Completed planned enrollment in AROANG1001, a Phase 1 clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic being developed for the treatment of mixed dyslipidemia

Completed discovery and optimization work and advanced ARO-Lung2, Arrowhead’s investigational RNAi therapeutic being developed for the treatment of chronic obstructive pulmonary disorder (COPD), into IND-enabling studies with a planned CTA filing in in the first half of 2021. ARO-Lung2 is against an undisclosed gene target and is the company’s second inhaled RNAi candidate to leverage the Targeted RNAi Molecule (TRiMTM) platform to the target pulmonary epithelium

Started a development program to address the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens. No additional details about this program are being disclosed at this time

Reported interim multiple-dose results on two cardiometabolic candidates ARO-APOC3, being developed as a potential treatment for patients with severe hypertriglyceridemia, and ARO-ANG3, being developed for the treatment of mixed dyslipidemia, showing high levels of reduction in APOC3, ANGPTL3, triglycerides, and other lipid parameters

Completed a regulatory submission to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis

Expanded Arrowhead’s senior management team with the hiring of Jim Hassard as chief commercial officer

Opened a second Research and Development facility in San Diego, which allows Arrowhead to tap into additional skill sets in one the country’s premier biotech hubs and also expands capacity for preclinical models to do more early research work in parallel